A Study of pathologic risk factors in postchemoreduced, enucleated specimens of advanced retinoblastomas in a developing Country

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 8, 2011, Pages 1017-1023

  Suryawanshi, Pallavi ^a   Ramadwar, Mukta ^a   Dikshit, Rajesh ^b   Kane, Shubhada V ^a   Kurkure, Purna ^b   Banavali, Shripad ^a   Viswanathan, Seethalakshmi ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Medical Oncology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHILD; ENUCLEATION; FEMALE; HUMAN; INDIA; INFANT; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROGNOSIS; RETINA TUMOR; RETINOBLASTOMA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EYE ENUCLEATION; FEMALE; HUMANS; INDIA; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 80052010169     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/2010-0311-OAR2     Document Type: Article

References (38)

1. Hurwitz RL, Shields CL, Shields JA, et al. Retinoblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:865-886.
2. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma; metastatic potential and clinical risk factors. Cancer. 1994; 73(3):692-698. (Pubitemid 24046614)
3. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol. 2002;38(6):411-415. (Pubitemid 34507285)
4. Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007;49(3):256-260. (Pubitemid 47236213)
5. Reddy VP, Honavar SG, Shome D, Shah K, Naik MN, Rao R. Demographics, clinical profile, management, and outcome of retinoblastoma in a tertiary care center in southern India [abstract]. J Clin Oncol. 2007;25(18S): 20011.
6. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46(8):2683-2691.
7. Chong EM, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chevez-Barrios P. Extensively necrotic retinoblastoma is associated with high risk prognostic factors. Arch Pathol Lab Med. 2006,130(11):1669-1672. (Pubitemid 44683795)
8. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923-931. (Pubitemid 34755545)
9. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199-1202.
10. Rubin CM, Robison LL, Cameron JD, et al. Intraocular retinoblastoma group V: an analysis of prognostic factors. J Clin Oncol. 1985;3(5):680-685. (Pubitemid 15119241)
11. Howarth C, Meyer D, Hustu HO, Johnson WW, Shanks E, Pratt C. Stage related combined modality treatment of retinoblastoma: results of a prospective study. Cancer. 1980;45(5):851-858. (Pubitemid 10129832)
12. Schvartzman E, Chantada G, Fandino A, de Davila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996; 14(5): 1532-1536. (Pubitemid 26134210)
13. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a prospective study of 172 patients treated in a single institution. Cancer. 1996;77(6):1206-1213. (Pubitemid 26080915)
14. Honavar SG, Singh AD, Shields CL. Postenucleation adjuvant therapy in high risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923-931. (Pubitemid 34755545)
15. Chantada GL, Dunkel IJ, de Dávila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069-1073. (Pubitemid 39013152)
16. White L. Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol. 1991;13(2):189-201.
17. Pratt CB, Fontanesi J, Chenaille P,et al. Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol. 1994;11(3):301-309. (Pubitemid 24153142)
18. Grabowski EF, Abramson DH. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am. 1987; 1(4):721-735. (Pubitemid 18063200)
19. Shields CL, Shields JA. Intraocular Tumors: A Text and Atlas. Philadelphia, PA: WB Saunders; 1992:305-391.
20. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53(5):661-671. (Pubitemid 16114627)
21. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820-823.
22. Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH. Clinicopathological features of retinoblastoma after primary chemoreduction. Arch Ophthalmol. 1998;116(7):887-893. (Pubitemid 28554778)
23. Demirci H, Eagle RC Jr, Shields CL, Shields JA. Histopathological findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol. 2003;121(8):1125-1131. (Pubitemid 36962166)
24. Gupta R, Vemuganti GK, Reddy VA, Honavar SG. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med. 2009;133(8):1210-1214.
25. Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77(9):544-548. (Pubitemid 23281450)
26. Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96(2):217-222. (Pubitemid 19049464)
27. Zimmerman LE. The registry of ophthalmic pathology, past, present and future. Trans Am Acad Ophthalmol Otolaryngol. 1961;65(1):51-113.
28. Marback EF, Arias VE, Paranhos A Jr, Soares FA, Murphree AL, Erwenne CM. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 2003;87(10):1224-1228. (Pubitemid 37193910)
29. Chantada GL, de Davila MT, Fandino A, et al. Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genet. 1999;20(3):133-140.
30. Messmer EP, Heinrich T, Hopping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98(2):136-141.
31. Rootman J, Hofbauer J, Ellsworth RM, Kitchen D. Invasion of the optic nerve by retinoblastoma: a clinicopathological study. Can J Ophthalmol. 1976; 11(2):106-114.
32. Brown DH. The clinicopathology of retinoblastoma. Am J Ophthalmol. 1976;61(3):508-514.
33. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1 ):41-48. (Pubitemid 32096384)
34. Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol. 2009;127(8):1006-1010.
35. Amemiya T, Yoshida H, Ishigooka H. Vitreous seeds in retinoblastoma, clinical significance and ultrastructure. Albrecht Von Graeies Arch Klin Exp Ophthalmol. 1979;211(3):205-213. (Pubitemid 9247511)
36. Ko EY, Ritchey ML. Current management of Wilms' tumor in children. J Pediatr Urol. 2009;5(1):56-65.
37. de Sutter E, Havers W, Hopping W, Zeller G, Alberti W. The prognosis of retinoblastoma in terms of survival: a computer assisted study, part II. Ophthalmic Paediatr Genet. 1987;8(2):85-88. (Pubitemid 17116751)
38. Kingston JE, Hungerford JL, Plowman PN. Chemotherapy in metastatic retinoblastoma. Ophthalmic Paediatr Genet. 1987;8(1):69-72. (Pubitemid 17035646)